An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Brineura

Chemical Namecerliponase alfa
Dosage FormInjection (intraventricular; 150 mg/5 ml)
Drug ClassEnzymes
SystemNervous
CompanyBioMarin Pharmaceutical Inc.
Approval Year2017

Indication

  • To slow the loss of ambulation associated with late infantile neuronal ceroid lipofuscinosis type 2 in patients ≥ 3 years of age.
Last updated on 11/5/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Brineura (Cerliponase Alfa) Prescribing Information 2017BioMarin Pharmaceutical Inc., Novato, CA
Document TitleYearSource
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2. 2019NICE
Clinical review report: Cerliponase Alfa (Brineura): (Biomarin Pharmaceutical (Canada) Inc.). 2019CADTH